HTL Biotechnology Launches €12 Million Sterile Hyaluronic Acid Production Line to Enable Heat-Sensitive Drug Combinations
Key Insights
HTL Biotechnology (search) inaugurated a new €12 million sterile hyaluronic acid production unit at its Javené site in France, part of a €100 million strategic investment plan through 2026.
The cutting-edge sterile manufacturing process enables combination of hyaluronic acid with heat-sensitive active molecules previously incompatible with traditional heat sterilization methods.
This innovation opens new therapeutic opportunities in ophthalmology and drug delivery by eliminating microbial contamination risks while maintaining pharmaceutical quality standards.
HTL Biotechnology (search) has inaugurated a new production unit dedicated to sterile hyaluronic acid manufacturing at its Javené site in France, marking a significant advancement in pharmaceutical-grade biopolymer production. The €12 million investment, announced during National Bioproduction and Biomedicines Day under the patronage of French President Emmanuel Macron, represents a key milestone in the company's €100 million strategic plan spanning 2022-2026.
Revolutionary Sterile Manufacturing Process
The new production line introduces a cutting-edge sterile manufacturing process that addresses a critical limitation in pharmaceutical formulation. This innovation enables the combination of hyaluronic acid with heat-sensitive active molecules that were previously incompatible with traditional heat sterilization methods. The mastery of aseptic processes eliminates any risk of microbial contamination while ensuring optimum pharmaceutical quality standards.
"This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery," according to the company's announcement.
Expanding Therapeutic Applications
The sterile hyaluronic acid manufacturing capability opens new therapeutic opportunities across multiple medical fields. The technology particularly benefits ophthalmology applications and drug delivery systems, where the combination of hyaluronic acid with heat-sensitive compounds can provide enhanced clinical outcomes for patients.
HTL Biotechnology (search)'s CEO François Fournier emphasized the strategic importance of this development: "I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients."
Specialized Training and Quality Assurance
To ensure the highest quality standards for this technically demanding production process, HTL Biotechnology (search) has implemented comprehensive in-house training programs. A specialized team of ten experts has been trained in the specific skills required for sterile hyaluronic acid production, focusing on aseptic procedures and handling protocols for this advanced product.
The company's commitment to quality extends beyond personnel training to encompass the entire production infrastructure. Production is scheduled to commence in 2026, following rigorous qualification and validation of all industrial equipment.
Strategic Market Position
With over 30 years of expertise in biopolymers, HTL Biotechnology (search) has established itself as a global leader in pharmaceutical-grade biopolymer development and production. The company specializes in hyaluronic acid, polynucleotides (search), and recombinant human collagen (search), serving healthcare companies developing treatments across ophthalmology, dermatology, medical aesthetics, and rheumatology.
The new sterile production capability strengthens HTL Biotechnology (search)'s position in the expanding biopolymer market. The investment pursues two primary strategic objectives: exploring new opportunities in bioproduction and reinforcing the company's role as a key player in future healthcare applications of hyaluronic acid.
Global Expansion and Recognition
HTL Biotechnology (search) operates with nearly 300 employees worldwide and maintains subsidiaries in Asia while constructing a neuromodulator production unit in Massachusetts. The company recently acquired a recombinant protein platform through its New Jersey subsidiary, with recombinant human collagen type III (search) (rhCOL3) as the most advanced product.
The inauguration coincided with the second National Biomanufacturing and Biomedicines Day, highlighting the strategic importance of French biomanufacturing and biomedical industries. As an active member of France Biolead (search), HTL Biotechnology (search)'s participation underscores the sector's critical role in addressing public health challenges.